Full Press Release Details
SAN FRANCISCO , July 31, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) will announce its financial results for the second quarter on Thursday, August 7, 2025, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/ 2:00 p.m. Pacific Time .
This press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home Page and Investors section of the Nektar website: https://ir.nektar.com/ . The web broadcast of the conference call will be available for replay through September 7, 2025.
To access the conference call by phone, please pre-register at Nektar Earnings Call Registration . All registrants will receive dial-in information and a PIN allowing them to access the live call.
About Nektar Therapeutics
Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in two Phase 2b clinical trials, one in atopic dermatitis and one in alopecia areata. Nektar's pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. Nektar, together with various partners, is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.
Corey Davis , Ph.D. LifeSci Advisors, LLC [email protected] 212-915-2577
Ahu Demir, Ph.D. LifeSci Advisors, LLC [email protected] 212-915-3820
Madelin Hawtin LifeSci Communications 603-714-2638 [email protected]
SOURCE Nektar Therapeutics